Iovance Biotherapeutics
IOVA
237 hedge funds and large institutions have $1.75B invested in Iovance Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 102 increasing their positions, 71 reducing their positions, and 50 closing their positions.
77% more call options, than puts
Call options by funds: $32.1M | Put options by funds: $18.1M
44% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 71
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
2.14% more ownership
Funds ownership: 99.24% → 101.39% (+2.1%)
5% less funds holding
Funds holding: 250 → 237 (-13)
20% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 50
33% less capital invested
Capital invested by funds: $2.6B → $1.75B (-$852M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$64.5M |
| 2 |
BlackRock
New York
|
+$54.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31.3M |
| 4 |
D.E. Shaw & Co
New York
|
+$25.6M |
| 5 |
Goldman Sachs
New York
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$130M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$60.9M |
| 3 |
O
OrbiMed
New York
|
-$50.3M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$39.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$17M |
IOVA Hedge Fund Activity: Q2 2022 in Review
237 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2022, worth a combined $1.75B — down 33% from $2.6B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of IOVA and 40 opened new positions — a net loss of 10 holders — while 71 trimmed existing stakes and 102 added.
The largest buyer was State Street, adding an estimated $64.5M. The largest seller was Wellington Management Group, cutting an estimated $130M.
- 237 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2022, down from 250 in Q1 2022.
- Funds reported $1.75B of Iovance Biotherapeutics stock for Q2 2022, down 33% quarter-over-quarter.
- 40 funds opened new Iovance Biotherapeutics positions in Q2 2022 and 50 closed out, a net change of -10 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2022 was State Street, an estimated $64.5M added.
- The largest Iovance Biotherapeutics seller in Q2 2022 was Wellington Management Group, an estimated $130M sold.
Based on aggregated 13F filings for Q2 2022.